2023 Was a tough 12 months for your biopharma industry, with many businesses downsizing and restructuring their workforces to stay afloat. There are signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and lifestyle sciences marketplace within the latter Portion of 2023 and have continued their upswing https://sites.google.com/view/bio-sites/blog